News

Curaxys obtains financing for the purchase of equipment with the help granted by Innplanta 2012

07/10/2013

Curaxys SL. is the unique Spanish biotechnology company that researches, develops, produces and commercializes biosimilars in a single integrated process for combating diseases of high incidence in society as breast cancer.

Curaxys hires five more technologists.

10/01/2013

Curaxys hires five more technologists with the support of the Inncorpora Program granted by the Ministry of Economy and Competitiveness.

One of the largest biopharmaceutical projects in Europe to be started at Tecnobahía.

14/12/2012

Curaxys S.L. and Obras Coman S.A. have signed a contract to excecute a Biopharma Plant to produce biological medicines and other recombinant proteins to cure different diseases like cancer.

Innovaxis, a novel company for “custom medicine”

21/03/2012

Innovaxis, first Enterprise that commercializes advances therapies and tissue regeneration integrating HTS services.

Strategic Alliance for cancer disease

A Technological and Commercial Strategic Alliance leading I+D of generic and biogeneric compounds for cancer disease.

UCA and Curaxys create a Cathedra in biopharmaceuticals in order to research biosimilar proteins

Curaxys CEO will dedicate their practice in biological drug development and will train researchers and biotechnology managers

Curaxys is ranked among the world top ten companies in the research of biologic generic medicines

19/03/2012

The Andalusian pharmaceutical company, Curaxys, is ranked among the world top ten companies.

More on Curaxys
We focus on the research, production and commercialization of recombinant proteins added value through the utilization of CuraMab® with specific human cell lines
Our expression system allows us to reach of recombinant protein levels that are clearly above those currently available.
We developed a downstream technological platform on the basis of our own laboratory data.
Copyright 2012 Curaxys. All Rights Reserved
Legal Advice